Because current knowledge of inhalational AMB is limited, a rigorous scientific approach is warranted to establish opt"1mal dose, frequency and durat"1on of administration. We therefore decided to study in detail the fu II potential of nebulised AMB in different formulations, with the aim of answering the following questions: What is the pharmacokinetic behaviour of nebulised AMB, which dose would be sufficient and which frequency of dosing? Does inhalation of AMB exert any adverse effects? What is the value of nebulised lipid formulations of AMB as compared to nebulised AMB-DOC? Can the efficacy be demonstrated in an animal model of invasive pulmonary aspergillosis? The primary aim of the work presented in this thesis was to evaluate the merits of inhalational AMB formulations in the prophylaxis and treatment of i.1vasive pulmonary aspergillosis. The thesis starts with an overview of lnvestigationa I antifunga Is. Agents that are currently in development for Aspergillus infections are discussed in a review (Chapter 2).

, , , ,
H.A. Verbrugh (Henri)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Ruijgrok, E. (2002, June 19). Inhalation of amphotericin B formulations for prevention and treatment of invasive pulmonary aspergillosis : an experimental study in rats. Retrieved from